Under a tenth of people that would benefit from obesity jabs such as Wegovy can access them, caution the global health agency as it publishes its first advice on the medications.
Considering in excess of 1,000,000,000 people worldwide now classified as obese, it is advocating for increased and just availability to GLP-1 medication.
Per forecasts, over two billion are projected to be obese by 2030 if no action is taken.
"Our new guidelines affirms that excess weight is a chronic disease that can be treated with holistic and ongoing treatment," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are significant barriers to broad availability to the injections that can help people shift significant weight, says the organization.
Weight-Loss Drug Scarcity
Even in the present best projected outlook, the supply of GLP-1 therapies might only reach approximately 100 million people – less than 10% of those who need them, per the health organization.
The guideline urges governments and firms to increase availability, through measures including patent sharing.
A patent on a key compound – the primary ingredient of the drug Wegovy – is due to expire in multiple countries in 2026.
How Weight-Loss Drugs Work
The injections replicate a body's own hormone to reduce digestion speed, curb appetite and increase the sense of being full so individuals reduce food intake.
Individuals usually begin shedding pounds after several weeks of commencing the regular doses.
Studies indicates people may put most of the weight back on after a year of halting the treatment, because their typical appetite come back.
Being carrying excess weight increases your risk for developing diseases, like type 2 diabetes, cardiovascular issues, stroke, and certain cancers.
Excess weight impacts individuals in every country and was linked to 3.7 million fatalities worldwide in 2024, as per the WHO.
